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RESULTS: 
AIMS: Apolipoprotein C-III (ApoC-III) is well recognized as a main determinant of triglyceride (TG) plasma concentration and plays 
a crucial role in coronary artery disease (CAD). However, data on Apo C-III glycoforms are only sparse so far. The aim of this study 
was to quantify Apo C-III glycoforms  in CAD patients and to assess their correlations with plasma lipids.  
METHODS: Apo C-III glycoforms were analysed by mass spectrometry in 55 subjects with clinically stable CAD (90.9% males, 
mean age 70.2±7.9 years) within the framework of the Verona Heart Study. 
 
 
Figure 1. Apo C-III glycoforms distribution  
Table 2.Correlation between Apo C-III glycoforms and plasma lipid profile, including Apo E and 
Apo B concentration 
% HDL LDL Chol TG Apo E Apo B Apo C-III  
tot 
Apo C-IIItot r=-0.120 
p=0.382 
r= 0.544 
p= 0.001 
r= 0.619 
p< 0.001 
r= 0.792 
p< 0.001 
r=0.683 
p<0.001 
r=0.599 
p< 0.001 
/ 
Apo C-III0% r= 0.182 
p= 0.183 
r=-0.317 
p= 0.018 
r=-0.314 
p= 0.020 
r=-0.421 
p= 0.001 
r=-0.434 
p= 0.001 
r=-0.292 
p= 0.030 
r=-0.351 
p= 0.009 
Apo C-III1% r=-0.356 
p= 0.008 
r= 0.337 
p= 0.012 
r= 0.280 
p= 0.038 
r= 0.438 
p= 0.001 
r= 0.457 
p< 0.001 
r= 0.288 
p= 0.033 
r= 0.382 
p= 0.004 
Apo C-III2% r= 0.234 
p= 0.085 
r=-0.074 
p= 0.594 
r=-0.010 
p= 0.944 
r=-0.086 
p= 0.531 
r=-0.095 
p= 0.490 
r=-0.040 
p= 0.769 
r=-0.091 
p= 0.508 
ApoC-III1/ 
Apo C-III0 
r=-0.285 
p= 0.035 
r= 0.391 
p= 0.003 
r= 0.362 
p= 0.007 
r= 0.485 
p< 0.001 
r= 0.517 
p< 0.001 
r= 0.350 
p= 0.009 
r= 0.445 
p= 0.001 
Table 1. Clinical and laboratory characteristics of the study group subdivided by  Apo C-III plasma concentration (*ANOVA test) 
Figure 2. Apo CIII Isoforms distribution according to PUFA intake. 
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Conclusions 
Our results suggest that Apo C-III 
glycoforms vary in their association with 
plasma lipids and apoliproteins. Thus, a 
measure of total Apo C-III may not strictly 
reflect the overall risk represented by the 
single isoform. In a comparable way to the 
concentration of total Apo C-III, the 
monosialylated isoform resulted to be 
statistically correlated with a less favorable 
lipid profile, including an increase of serum 
total and LDL cholesterol, TG, Apo B and 
Apo E. As a consequence,  a relatively 
elevated amount of this isoform seemed to 
characterize the same “harmful” lipid 
situation that was observed when total Apo 
C-III is elevated. 
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Apo C-III<8.7(mg/dl) 8.7≤Apo C-III<11.7(mg/dl) 11.7≤Apo C-III<13.8(mg/dl) Apo C-III≥13.8(mg/dl) P* 
Age 60.62±7.70 59.88±8.94 62±4.11 58.36±10.54 NS 
Chol tot (mM/L) 3.90±0.36 4.15±0.53 4.56±0.84 5.07±1.01 <0.001 
LDL (mM/L) 2.55±0.31 2.72±0.58 3.08±0.81 3.45±0.94 0.001 
HDL (mM/L) 1.15±0.27 1.11±0.29 1.07±0.28 1.09±0.29 NS 
TG (mM/L) 1.01±0.25 1.62±0.69 2.10±0.58 2.67±1.06 <0.001 
Apo A (g/L) 1.41±0.23 1.49±0.16 1.51±0.24 1.55±0.21 0.096 
Apo B (g/L) 0.64±0.13 0.71±0.17 0.79±0.29 0.97±0.26 <0.001 
Apo E (g/L) 0.03±0.003 0.03±0.01 0.04±0.01 0.05±0.02 <0.001 
Apo C-III (mg/dL) 6.88±1.56 10.26±1 12.88±0.57 16.52±1.91 <0.001 
